Pathologically confirmed adenocarcinoma of the pancreas
Patients with unresectable disease based on institutional standardized criteria of unresectability or patients whose disease appeared potentially resectable on axial CT imaging but were found unresectable at surgery
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. Age ≥ 18
Patients with biliary or gastroduodenal obstruction must have drainage or surgical bypass prior to starting treatment
Patients with radiographically assessable disease
Adequate bone marrow, hepatic and renal function: -Hemoglobin \>10.0 g/dL, absolute neutrophil count \> 1.5 x 10\^9/L, platelet count \> 100 x 10\^9/L. -Aspartate transaminase (AST or SGOT) and alanine transaminase (ALT or SGPT) should be ≤ 3 x upper limit of normal (ULN). -Total bilirubin \< 2 mg/dL. Patients with elevated bilirubin due to obstruction should be stented and their bilirubin should decrease to \< 2 mg/dL prior to study entry. - Creatinine \< 3 mg/dL or Creatinine clearance \> 40 mL/min (calculated according to Cockroft and Gault)
You may not be if
Evidence of metastatic disease in the major viscera or peritoneal seeding or ascites
Gastric or duodenal obstruction
Previous peripheral neuropathy
Previous irradiation to the planned field; previous chemotherapy for pancreatic cancer
Malignancy (within the past two years) except non-melanomatous skin cancer or carcinoma in situ of the cervix, uterus, or bladder
Clareo Health | Low-dose Radiotherapy Plus Chemotherapy With Gem-based Doublets and Stereotactic Radiotherapy for Advanced Pancreatic Cancer
